Compartmentalized immune responses and the local microbiota determine mucosal and systemic immunity against SARS-CoV-2

Jonas Buttenschön¹, Stefan Vogt¹ and Jochen Mattner¹,²✉

© The Author(s) 2021

Cellular & Molecular Immunology (2022) 19:130–132; https://doi.org/10.1038/s41423-021-00822-5

The clinical manifestations of SARS-CoV-2 infection, which is the cause of the coronavirus disease 2019 (COVID-19) pandemic, are highly variable and range from asymptomatic carriage or mild symptoms to severe disease involving different organ systems. However, the specific factors influencing individual clinical outcomes remain unclear. Thus, to characterize the versatile interplay of mucosal and systemic immune responses with the local microbiome and the viral load, as well as its impact on the course of the disease, Smith et al. performed integrated analyses of nasopharyngeal swabs and plasma samples from COVID-19 patients with varying degrees of illness severity. They observed that spike-specific neutralizing antibodies were heterogeneous between paired plasma samples and nasopharyngeal swabs from individual SARS-CoV-2 patients, suggesting a tissue-dependent regulation of humoral immune responses. Their study also confirmed that systemic inflammatory responses were associated with viral load. Interestingly, dysbiosis of the local microbiota and an accumulation of (facultative) pathogenic bacteria in the nasopharynx, frequently reported in secondary respiratory infections, were linked to mucosal inflammation and severe COVID-19. Conversely, the levels of cytokines, including IL-33 and different interferons that might be important for viral control, were reduced. Thus, Smith et al. revealed the nasopharyngeal microbiome as a novel player influencing local and systemic immune responses to SARS-CoV-2 and subsequently the clinical outcome of COVID-19 [1].

The clinical manifestations following SARS-CoV-2 infection are highly variable. Viral replication, as well as comorbidities, age, sex, the immune response of the host, or a combination of any or all of these factors, have been suggested to influence the outcome of disease [2, 3]. Although it is known that SARS-CoV-2 suppresses innate and antiviral immunity, causes peripheral lymphopenia, and promotes hyperinflammatory macrophage/monocyte activation [4], the distinct pathophysiologic mechanisms underlying severe COVID-19 have remained largely unknown. Thus, to characterize disease severity-determining factors, Smith et al. studied 15 patients with moderate, 11 with severe, and 23 with critical COVID-19 at the time of hospitalization as well as 12 age- and sex-matched healthy controls [1]. SARS-CoV-2 infections were confirmed or excluded by PCR. Plasma and nasopharyngeal swab samples were collected from patients and controls 8–12 days after the onset of disease, and systemic as well as mucosal SARS-CoV-2 spike-specific antibodies, cytokines, viral loads, and bacterial communities were evaluated.

The authors described, dependent on the severity of disease, an increasing frequency and intensity of spike-specific IgG and IgA antibodies in plasma and nasopharyngeal samples of patients, as reported in previous studies [5, 6]. The neutralization activity of these antibodies also increased with the severity of the disease. Spike-specific IgG or IgA antibodies, however, were substantially less frequent in nasopharyngeal secretions than in the blood. Surprisingly, there was only a poor correlation of the antibody titers and their neutralization capacity between plasma and nasopharyngeal samples within a single individual. Interestingly, two patients with moderate disease developed antibodies neither in their plasma nor in their nasopharyngeal secretion, while two other patients—with the critical disease—did not seroconvert but exhibited strong nasopharyngeal antibody responses. Thus, a tissue site-specific regulation of the humoral immune response in SARS-CoV-2 patients exists at the early stages of the disease. Indeed, the clinical outcome of infection in these four patients compared to the rest of the COVID-19 cohort will be of interest.

Of the 46 cytokines quantified in this study, 13 and 7 cytokines showed different levels between plasma and nasopharyngeal samples of healthy controls and patients with COVID-19, respectively. These differences included enhanced concentrations of different inflammatory cytokines in the plasma and decreased concentrations of interferons in mucus secretions, as previously reported [7, 8]. Smith et al. confirmed that interindividual differences in total protein or mucus content did not account for the differences observed in nasopharyngeal cytokine concentrations. Importantly, the concentrations of IL-6, IL-10, fibroblast growth factor, PD-L1, TNF, IL-1β, and IL-1RA were significantly increased in the plasma of patients with severe disease, while that of IFN-α2 was decreased. In contrast, fms-related receptor tyrosine kinase 3 ligand, epidermal growth factor (EGF), CXCL1 (GROα), PDGF-AA, IL-7, and TGF-α accumulated in significantly greater amounts in nasopharyngeal samples with worsening disease. Only CCL2 and VEGF levels were enhanced in tissue samples from both tissue sites. Thus, similar to the observed antibody responses,
these data also suggest a compartment-specific regulation of cytokine responses. The authors further discuss that some of these inflammatory cytokines might influence local mucosal antibody production, although the interferon response did not show any obvious correlations with the virus-specific antibody response.

Viral load was also increased in but again poorly correlated between plasma and nasopharyngeal samples. Interestingly, while the viral load in the plasma increased with a more severe disease, the nasopharyngeal viral load was largely independent of the clinical presentation. Applying multidimensional scaling (MDS), the authors observed a positive association of the viral load with IL-33, IFN-γ, IFN-α/β, and IFN-λ3, that might be important for viral control. The accumulation of *Staphylococcus* spp. might thereby enhance viral load, whereas *Prevotella*, *Streptococcus*, *Peptostreptococcus*, and *Clostridia* drive the release of inflammatory cytokines and presumably aggravate disease independent of viral load.

In contrast, *Corynebacterium* inhibit the expression of CCL2 and thus the influx of inflammatory monocytes into nasopharyngeal tissues. EnC endothelial cell, EpC, epithelial cell, VEGF vascular endothelial growth factor, FGF fibroblast growth factor, CSF-3 colony-stimulating factor 3.

**Fig. 1** Compartamentalized immune responses characterize acute infection with SARS-CoV-2. Viral load correlates positively with humoral immune responses and the release of cytokines in the plasma. In contrast, SARS-CoV-2 infection either directly or indirectly disrupts the homeostasis of the local commensal microbiota in the nasopharynx, resulting in reduced levels of cytokines, including IL-33, IFN-γ, IFN-α/β, and IFN-λ3, that might be important for viral control. The accumulation of *Staphylococcus* spp. might thereby enhance viral load, whereas *Prevotella*, *Streptococcus*, *Peptostreptococcus*, and *Clostridia* drive the release of inflammatory cytokines and presumably aggravate disease independent of viral load. In contrast, *Corynebacterium* inhibit the expression of CCL2 and thus the influx of inflammatory monocytes into nasopharyngeal tissues. EnC endothelial cell, EpC, epithelial cell, VEGF vascular endothelial growth factor, FGF fibroblast growth factor, CSF-3 colony-stimulating factor 3.
disruption of local epithelial barrier function, leading to the escape of potential pathobionts and resulting in systemic manifestations. In summary, the study identifies new interactions among the virus, the microbiota, and the immune response of the host during infection with SARS-CoV-2, which may help to uncover new strategies for identifying individuals at risk for developing severe disease. However, the respective triggers of inflammatory cytokine production in hyperinflammatory COVID-19 syndrome need to be identified.

REFERENCES
1. Smith N, Goncalves P, Charbit B, Grzelak L, Beretta M, Planchais C, et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat Immunol. 2021;22:1428–39. https://doi.org/10.1038/s41590-021-01028-7.
2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6. https://doi.org/10.1038/s41586-020-2521-4.
3. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–20. https://doi.org/10.1016/S0140-6736(20)30920-X.
4. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184:1671–92. https://doi.org/10.1016/j.cell.2021.02.029.
5. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147:545–55 e549. https://doi.org/10.1016/j.jaci.2020.10.040.
6. Zhou R, To KK, Wong YC, Liu B, Li X, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53:864–877.e865. https://doi.org/10.1016/j.immuni.2020.07.026.
7. Bastard P, Rosen LB, Zhang Q, Michalidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. https://doi.org/10.1126/science.abc6027.
8. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24. https://doi.org/10.1126/science.abc6027.

FUNDING
Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Jochen Mattner.

Reprints and permission information is available at http://www.nature.com/reprints

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021